Capecitabine and Oxaliplatin Alone or in Combination With Cetuximab as First-Line Treatment for Metastatic EGFR [epidermal growth factor receptor]-Positive Colorectal Cancer, A Randomized Multicenter Phase II Trial

Trial Profile

Capecitabine and Oxaliplatin Alone or in Combination With Cetuximab as First-Line Treatment for Metastatic EGFR [epidermal growth factor receptor]-Positive Colorectal Cancer, A Randomized Multicenter Phase II Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Cetuximab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2012 Actual end date (1 Feb 2006) added as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jun 2008 Results published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top